Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Victoria, Galan"'
Autor:
María Cristina Ortega, Isabel Machin-Diaz, Michelle Naughton, Inmaculada Pérez-Molina, Jennifer García-Arocha, Jose Manuel García-Domínguez, Haydee García-Briceño, Rafael Lebron-Galan, Virginia Vila-Del Sol, Victor Quintanero-Casero, Rosa García-Montero, Victoria Galan, Leticia Calahorra, Celia Camacho-Toledano, Maria Luisa Martinez-Gines, Denise Fitzgerald, Diego Clemente
Publikováno v:
IBRO Neuroscience Reports, Vol 15, Iss , Pp S285-S286 (2023)
Externí odkaz:
https://doaj.org/article/8f1a60fd6bfb46f7ba24766efa182080
Publikováno v:
In Journal of Engineering and Technology Management October-December 2019 54:67-80
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Susana Sainz de la Maza, Israel Thuissard, Andy Castro, Lucienne Costa-Frossard, Carmen Muñoz, Carlos López de Silanes, Julia Sabin, Hugo Martín, Yolanda Aladro, Ignacio Casanova, Irene Moreno, M Luisa Martínez-Ginés, Mayra Gómez-Moreno, Victoria Galan, Sarai Urtiaga, Lucía Ayuso, Elena Rodríguez-García, Celia Oreja-Guevara, Belen Pilo, Pedro Sánchez, Virginia Meca-Lallana, J.A. García-Merino, Laura Borrega, Alberto Lozano, Judit Díaz-Díaz
Publikováno v:
Journal of Neurology. 267:2362-2371
Dimethyl fumarate (DMF) tolerability and safety in multiple sclerosis (MS) has been analyzed in randomized clinical trials. Real-life studies are needed to assess possible harms of this therapy in a wider MS population. To evaluate DMF tolerability,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1fe69e36e011ba058e80fab4196ca64f
https://doi.org/10.1007/s00415-020-09848-7
https://doi.org/10.1007/s00415-020-09848-7
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Julia, Sabin, Sarai, Urtiaga, Belen, Pilo, Israel, Thuissard, Victoria, Galan, Susana, Sainz de la Maza, Lucienne, Costa-Frossard, Mayra, Gómez-Moreno, Judit, Díaz-Díaz, Celia, Oreja-Guevara, M Luisa, Martínez-Ginés, Alberto, Lozano, Laura, Borrega, Lucía, Ayuso, Andy, Castro, Pedro, Sanchez, Virginia, Meca-Lallana, Carmen, Muñoz, Ignacio, Casanova, Carlos, López de Silanes, Hugo, Martín, Elena, Rodriguez-García, Irene, Moreno, Juan Antonio, García-Merino, Yolanda, Aladro, Cristina, Andreu
Publikováno v:
Journal of neurology. 267(8)
Dimethyl fumarate (DMF) tolerability and safety in multiple sclerosis (MS) has been analyzed in randomized clinical trials. Real-life studies are needed to assess possible harms of this therapy in a wider MS population.To evaluate DMF tolerability, s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::93d3d3060a6f10c8948812795adeb01b
https://pubmed.ncbi.nlm.nih.gov/32350647
https://pubmed.ncbi.nlm.nih.gov/32350647
Autor:
Alberto Lozano-Ros, Susana Sainz de la Maza, Lucía Ayuso, Judit Díaz-Díaz, Belen Pilo de la Fuente, Julia Sabin, Israel Thuissard, Laura Borrego, Andy Castro, Carmen Muñoz, Carlos López de Silanes, Pedro Sánchez, J.A. García-Merino, Ignacio Casanova, Cristina Andreu-Vázquez, Rosario Blasco, Mayra Gómez-Moreno, José M. García-Domínguez, Virginia Meca-Lallana, Victoria Galan, Yolanda Aladro, Lucienne Costa-Frossard, Hugo Martín, Elena Rodríguez-García, Celia Oreja-Guevara
Background: Dimethyl fumarate (DMF) has demonstrated efficacy in phase III studies. However, real-world data are still limited. Objective: The objective of this study was to describe the profile of patients who receive DMF and to assess the effective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15099d0873117e1cc82c6be18e2276fe
https://hdl.handle.net/11268/9901
https://hdl.handle.net/11268/9901
Autor:
Ignacio Casanova, M. Angel Garcia-Martinez, Guillermo Izquierdo, Victoria Galan, Ana Maria Arias-Leal, Roberto Alvarez-Lafuente, Silvia Pérez-Pérez, Rafael Arroyo, Marta Garcia-Montojo, Maria Inmaculada Dominguez-Mozo, Jose Luis Santiago, Macarena Rus
Publikováno v:
European Journal of Clinical Investigation. 47:158-166
Background One of the risk factor to develop progressive multifocal leukoencephalopathy (PML) among natalizumab-treated patients is the presence and high levels of anti-JCV antibodies. Our purpose was to test the association of different clinical and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ffd251ba51cefb48671747dfb0aa56d
https://doi.org/10.1111/eci.12721
https://doi.org/10.1111/eci.12721
Autor:
Isabel Ortega-Madueño, Roberto Alvarez-Lafuente, Eulalia Rodríguez-Martín, Priscila Ramos-Mozo, Victoria Galan, Rafael Arroyo, Ana Maria Arias-Leal, Ignacio Casanova, Luisa M. Villar, Marta Garcia-Montojo, Maria Inmaculada Dominguez-Mozo, María Ángel García-Martínez
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a832d45c9feef67114cd23149e26ce58
https://doi.org/10.1002/eji.201948423/v3/response1
https://doi.org/10.1002/eji.201948423/v3/response1